Heart Test Laboratories Inc

Heart Test Laboratories, Inc. is a medical technology company focused on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.

Southlake, Texas, Jan. 23, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on January 20th, 2023, by HeartSciences (NASDAQ: HSCS; HSCSW), please note that in the second paragraph the fireside chat time was at 11:30 a.m. Eastern Time should be corrected to 11:00 a.m. Eastern Time on Wednesday, January 25th.   The corrected release follows:

Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th

Southlake, Texas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG), a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating in the Healthcare IT Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, being held virtually on Wednesday, January 25th, 2023.

HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th

Southlake, TX, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced it has appointed David R. Wells to its Board of Directors, effective December 28, 2022. Patrick Kanouff has contemporaneously resigned from the Board of Directors.

HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive

Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results

Southlake, Texas, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today announced that it has entered into a multi-year collaboration agreement with Rutgers University (Rutgers), one of America's leading public research universities.

HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms

Southlake, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be presenting at the 2022 RHK Disruptive Growth Conference being held December 5-6, 2022 at the offices of Reed Smith in New York City.

HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022

Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating at the at the 11th Annual Benchmark Discovery One-on-One Investor Conference which is being held on December 1, 2022, at the New York Athletic Club in New York City.

HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022

Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification

HeartSciences' MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events

Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues

HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG

Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences' MyoVista Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences' MyoVista

HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction

Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS) (NASDAQ: HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, will be presenting at the 15th annual LD Micro Main Event being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

HeartSciences to Present at the LD Micro Main Event XV on October 26th

SOUTHLAKE, TX / ACCESSWIRE / October 6, 2022 / Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois. Mr. Simpson is scheduled to present on Wednesday, October 12th at 1:30 p.m.

HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th

Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista®

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results

Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that management has been invited to participate and showcase the company's technology at the Inauguration Ceremony of the Center for Innovation at the Rutgers Robert Wood Johnson University Hospital on September 14, 2022, in New Brunswick, New Jersey.

HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.

HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year

HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results

Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW)  (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness, today announced that Andrew Simpson, CEO, and Chairman of HeartSciences, will be participating in the Benzinga All Access event taking place on July 15, 2022.

HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th

SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness, today announced the pricing of its initial public offering of 1,500,000 units, each consisting of one share of common stock (the “Common Stock”) and a warrant (the “Warrants”) to purchase one share of Common Stock, at a public offering price of $4.25 per unit for aggregate gross proceeds of approximately $6.375 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Each unit will immediately separate into one share of Common Stock and one Warrant. Each Warrant permits the holder to purchase one share of Common Stock at an exercise price of $4.25 per share, exercisable until the fifth anniversary of the issuance date.

News for Heart Test Laboratories Inc Stock (HSCS)